RCS - Redx Pharma Limited - Appointment of Chief Medical Officer
REDX PHARMA LIMITED
Redx Bolsters Gastroenterology Expertise with Appointment of Chief Medical Officer
Mei-Lun Wang, M.D., joins as Chief Medical Officer, strengthening the Company's clinical expertise in gastroenterology
Clinical leadership also further supported by the recent appointment of Bernard Coulie, M.D., Ph.D., to the Board of Directors
Alderley Park, UK, 2 September 2026 Redx Pharma Ltd ("Redx" or the "Company"), a clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, announces the appointment of Mei-Lun Wang, M.D., as Chief Medical Officer (CMO) on a permanent basis, further strengthening the Company's clinical leadership and gastroenterology expertise. This complements the appointment of Bernard Coulie, M.D., also a gastroenterologist, to the Board of Directors of the Company, as announced on the 27 August 2026.
Dr. Wang, CMO, Redx commented: "I am thrilled to join Redx at such an exciting time in the Company's journey. The opportunity to help advance a novel therapy for patients living with fibrostenotic Crohn's disease - an area of significant unmet medical need - is incredibly compelling. RXC008 is one of the most exciting programs in the inflammatory bowel disease landscape and I look forward to working with the team with the goal to generate clinical evidence and establish a regulatory framework to bring a new therapeutic treatment option to patients. For many patients, surgery is often their only option; so together we have the opportunity to make a meaningful difference for people affected by this challenging disease."
Dr. Wang is a US-based paediatric gastroenterologist who completed her fellowship training at the Children's Hospital of Philadelphia, where she was an Assistant Professor of Paediatrics at the Perelman School of Medicine at the University of Pennsylvania. With over 25 years' experience, Dr. Wang has spent 12 years in drug development at both big pharma and small biotech companies, leading Immunology & Inflammation (I&I) programs through early-stage clinical trials and post-approval commitment studies. As an expert in gastroenterology, Dr. Wang will collaborate with the STAR consortium (Stenosis Therapy and Anti-Fibrotic Research), a collaboration of academicians, clinicians and pharma companies who are actively engaged in research and supporting the establishment of a regulatory pathway for new therapies targeting fibrostenotic Crohn's disease.
Dr. Florian Rieder, Principal Investigator for the RXC008 Phase 2 trial and Co-Founder of the STAR Consortium commented: "I am delighted to be working with Dr. Wang on the RXC008 clinical trial, and the STAR Consortium is proud to support her and the Redx development program. Dr. Wang is highly respected within the gastroenterology community and her expertise and leadership from both a clinical and drug development perspective will be invaluable as we advance the RXC008 Phase 2 trial. I look forward to working together to advance this promising, novel therapeutic treatment option towards delivering meaningful outcomes for patients."
RXC008, A Novel GI restricted pan-ROCK Inhibitor
Rho-associated coiled-coil forming protein kinase (ROCK) is well established as an anti-fibrotic target and is known to consist of two isoforms, ROCK 1 and 2. RXC008 is a potent, oral, small molecule non-systemic ROCK1/2 inhibitor designed to avoid the significant cardiovascular side effects of systemic pan-ROCK inhibitors, including tachycardia and hypotension, by being restricted to the GI-tract via high efflux and low permeability. This results in virtually no systemic breakthrough, with the molecule being rapidly metabolised by paraoxonase enzymes in the plasma should any breakthrough occur. Data from the Phase 1 trial showed favorable tolerability and tissue exposure with no clinically relevant breakthrough or hypotension observed, and a favorable safety profile with no serious adverse events. RXC008 has an open IND in the US and was granted FDA fast track designation in January 2026. RXC008 is anticipated to commence a Phase 2 clinical trial in the fourth quarter of 2026, with topline data expected in mid-2028.
About Fibrostenotic Crohn's Disease (FSCD)
Crohn's disease affects 1.7 million[1] people globally and over 70,000 new cases are diagnosed each year. More than 50% of patients with Crohn's disease can develop significant fibrosis and stricture formation within ten years after diagnosis[2]; this fibrosis associated with Crohn's disease is known as fibrostenotic Crohn's disease ("FSCD"). The current management of fibrotic strictures of the gastrointestinal tract is primarily surgical as no drugs are specifically approved to tackle fibrosis, which can progress despite intervention with current standard of care anti-inflammatory therapies. Once a patient is suffering from FSCD, healthcare costs can increase by more than an additional $80k[3] per patient per year due to additional hospitalizations and treatment compared to non-fibrotic Crohn's disease, creating a health economic burden in this area of high unmet need.
For further information, please contact:
Redx Pharma Limited
UK Headquarters
Caitlin Pearson, Head of Communications
FTI Consulting
T: +44 (0)203 727 1000
Simon Conway
About Redx Pharma
Redx Pharma is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, developing therapeutic treatment options in areas of high unmet need. The Company has a leading position in therapies targeting the ROCK pathway and its lead asset RXC008, a gut-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is anticipated to commence a Phase 2 clinical trial in the fourth quarter of 2026. The Company's pipeline also includes zelasudil (RXC007), a next-generation selective ROCK2 inhibitor, and a novel Discoidin Domain Receptor (DDR) program targeting chronic kidney disease, currently in pre-clinical studies.
Important Information and Where to Find it
In connection with the proposed transaction between Redx and Skye Bioscience, Inc. ("Skye") (the "Transaction"), Skye intends to file with the U.S. Securities and Exchange Commission (the "SEC") a proxy statement (the "Proxy Statement"), the definitive version of which will be sent or provided to the Skye's stockholders. Skye may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the Proxy Statement or any other document that Skye may file with the SEC or send to its stockholders. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Stockholders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Skye through the website maintained by the SEC at www.sec.gov or the Skye's website at https://ir.skyebioscience.com/sec-filings/all-sec-filings.
No Offer or Solicitation
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNRABIGDCUGGDGLB
Recent news on FTI Consulting
See all newsBrief: Fti Consulting Appoints Christina Morris As A Senior Managing Director
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
RCS - Redx Pharma Limited - Appointment of Chief Medical Officer
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition